These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
352 related items for PubMed ID: 16284425
1. Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins in children with Graves' disease. Shibayama K, Ohyama Y, Yokota Y, Ohtsu S, Takubo N, Matsuura N. Endocr J; 2005 Oct; 52(5):505-10. PubMed ID: 16284425 [Abstract] [Full Text] [Related]
2. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects. Takasu N, Oshiro C, Akamine H, Komiya I, Nagata A, Sato Y, Yoshimura H, Ito K. J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248 [Abstract] [Full Text] [Related]
4. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay. Maugendre D, Massart C. Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931 [Abstract] [Full Text] [Related]
7. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease]. Chen W, Man N, Li YS, Shan ZY, Teng WP. Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113 [Abstract] [Full Text] [Related]
12. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment. Quadbeck B, Hoermann R, Hahn S, Roggenbuck U, Mann K, Janssen OE. Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228 [Abstract] [Full Text] [Related]
15. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P. Thyroid; 1998 Feb; 8(2):119-24. PubMed ID: 9510119 [Abstract] [Full Text] [Related]
16. Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease. Yamano Y, Takamatsu J, Sakane S, Hirai K, Kuma K, Ohsawa N. Thyroid; 1999 Aug; 9(8):769-73. PubMed ID: 10482368 [Abstract] [Full Text] [Related]
19. Clinical validity of a new commercial method for detection of TSH-receptor binding antibodies in sera from patients with Graves' disease treated with antithyroid drugs. Massart C, Orgiazzi J, Maugendre D. Clin Chim Acta; 2001 Feb; 304(1-2):39-47. PubMed ID: 11165197 [Abstract] [Full Text] [Related]
20. Interaction of thyroid-stimulating antibody with Graves' thyroid-stimulating hormone-binding antibody. Ochi Y, Kajita Y, Hamazu M, Nagata A. Horm Res; 2003 Feb; 59(5):222-8. PubMed ID: 12714785 [Abstract] [Full Text] [Related] Page: [Next] [New Search]